KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Current Deferred Revenue (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Current Deferred Revenue for 18 consecutive years, with $636.2 million as the latest value for Q1 2026.

  • For Q1 2026, Current Deferred Revenue rose 2.73% year-over-year to $636.2 million; the TTM value through Mar 2026 reached $636.2 million, up 2.73%, while the annual FY2025 figure was $553.0 million, 11.9% down from the prior year.
  • Current Deferred Revenue hit $636.2 million in Q1 2026 for Regeneron Pharmaceuticals, up from $553.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $636.2 million in Q1 2026 and bottomed at $381.1 million in Q2 2023.
  • Average Current Deferred Revenue over 5 years is $527.1 million, with a median of $545.6 million recorded in 2025.
  • Year-over-year, Current Deferred Revenue tumbled 32.7% in 2023 and then soared 53.77% in 2024.
  • Regeneron Pharmaceuticals' Current Deferred Revenue stood at $477.9 million in 2022, then dropped by 3.98% to $458.9 million in 2023, then soared by 36.78% to $627.7 million in 2024, then dropped by 11.9% to $553.0 million in 2025, then grew by 15.05% to $636.2 million in 2026.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $636.2 million, $553.0 million, and $545.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.